Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2... March 24, 2026 FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... January 19, 2023 Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο January 25, 2020 Lawmaker Dad Raises Awareness For RSV, An Illness He’d Never Heard... November 20, 2019 Load more HOT NEWS Engaging People with Low-Grade Glioma in Cancer Research A peek behind the scenes: Just how are our funding decisions... Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates...
